"Potential drug treatments are tested on paper, in laboratories and eventually in thousands of people. But every drug that goes through this cycle â€“ every drug that FDA approves â€“ carries some risk. One of the first lines of defense against "...
Clinical consequences of overdosage with OptiMARK have not been reported. Treatment of overdose is directed toward supporting vital functions and prompt institution of symptomatic therapy. OptiMARK has been shown to be dialyzable [see CLINICAL PHARMACOLOGY].
OptiMARK is contraindicated in patients with:
- chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m²)
- acute kidney injury
- known hypersensitivity reactions to gadolinium, versetamide or any of the inert ingredients.
Last reviewed on RxList: 12/15/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional OptiMARK Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.